Human EGFR-T790M/L861Q Stable Cell Line-Ba/F3

The EGFR-T790M/L861Q gene mutation is a specific alteration that occurs in the Epidermal Growth Factor Receptor (EGFR) gene, which is responsible for coding the EGFR protein. This protein is a type of receptor tyrosine kinase that plays a critical role in cell growth, proliferation, and differentiation in response to the binding of epidermal growth factors.

The EGFR-T790M/L861Q mutation is a complex mutation that involves two specific alterations: T790M and L861Q. The T790M mutation occurs at amino acid 790, resulting in the substitution of threonine with methionine. The L861Q mutation occurs at amino acid 861, leading to the substitution of leucine with glutamine. These alterations collectively impact the structure and function of the EGFR protein, causing its constitutive activation and promoting cell growth, survival, and migration.

This specific mutation is of significant concern in the context of acquired resistance to EGFR inhibitors, such as gefitinib and erlotinib, which are commonly used in the treatment of EGFR-mutant lung cancers. The EGFR-T790M/L861Q mutation can develop over time as a result of selective pressure from EGFR inhibitor therapy, leading to treatment resistance and limited treatment options for patients.

Understanding the mechanisms underlying the EGFR-T790M/L861Q mutation and its impact on cancer progression is crucial for the development of new targeted therapies. Research on this mutation is ongoing, and efforts are being made to identify inhibitors or combination treatments that can effectively overcome the resistance caused by this mutation, providing improved outcomes for patients with EGFR-mutant cancers.